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ABSTRACT
Chloroquine is the first-line therapy against the asexual stages of Plasmodium vivax. 
There is a high variation of chloroquine plasma levels after therapeutic doses, which can lead 
to inadequate exposure to the drug. The gender influence was low regarding the disposition 
of the drug, which is relevant as there are significant physiological variations between male 
and female patients. The objective of the study was to investigate whether gender modifies 
the pharmacokinetics parameters of chloroquine in patients with malaria vivax. A prospective 
study was performed in male and female adult patients using chloroquine (total dose of 
25 mg/kg for three days) combined with primaquine. Serial blood samples were collected at 
admission and up to 672 h post-administration of the drugs. Chloroquine was measured in 
plasma samples by high-performance liquid chromatography with fluorescence detection. A 
non-compartmental analysis was used for modeling the data. A total of 26 male and 25 female 
patients were enrolled in the study. The pharmacokinetic parameters of chloroquine were 
similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum 
concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0–28) 
of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the 
volume of distribution (V/f) of 1869 L and 1936 L. The study results suggest that a similar 
dose regimen of chloroquine combined with primaquine provides a comparable pattern of 
exposure in male and female patients. 
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INTRODUCTION
Chloroquine is a 4-aminoquinoline used for the treatment of malaria caused 
by Plasmodium vivax, as well as for autoimmune and rheumatic diseases1-4. 
The pharmacokinetic parameters of chloroquine were described in a number of 
population groups and in healthy volunteers, aside from malaria patients. These 
investigations reported a high variation in the pharmacokinetics of the drug within 
and between-individuals and also described several predictors of variation of 
chloroquine blood levels that can affect the exposure and the treatment outcome5-8. 
Only a few studies evaluated the influence of a person’s gender on the disposition of 
chloroquine, which could be relevant, asthe physiological differences between male 
and female patients can alter the pharmacokinetics parameters of some drugs, which 
could influence the therapeutic efficacy and the incidence rates of adverse reactions9.
The present study aimed at investigating whether the gender modifies the 
pharmacokinetics parameters of chloroquine in patients with malaria vivax, using 
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a dose of 25 mg/kg in a three-day course with concurrent 
administration of primaquine2.
MATERIALS AND METHODS
Study site and patients
A prospective study was carried out in the municipality 
of Anajas, Para State, North of Brazil, from August 2018 to 
July 2019. Patients of bothgenders , aged > 18 years, with 
mono-infection by P. vivax were admitted in the study. The 
exclusion criteria were the presence of signs or symptoms 
of severe malaria, positive pregnancy test, regular use of 
tobacco or ethanol, known hypersensitivity to chloroquine, 
the use of antimalarial drugs within three months prior 
to the study, and those who disagreed or did not sign the 
consent form.
Treatment and follow-up
The treatment followed the recommendations of the 
World Health Organization, and consisted of chloroquine 
diphosphate in the total dose of 25 mg/kg for three days with 
primaquine diphosphate in a total dose of 3.0-3.5 mg/kg for 
seven days2. The drugs were provided by Farmaguinhos 
- Fundação Oswaldo Cruz/ Rio de Janeiro, Brazil. All 
treatments were supervised by the research team. Vomiting 
and other adverse reactions were monitored for 2 hours 
after the antimalarial drug intake. The patients were invited 
to return for the follow-up or when there were signs and 
symptoms suggestive of malaria. A parasite count and 
clinical interview were performed at each visit. 
Blood sample collection 
Blood samples (4 mL) were taken for the measurement 
of chloroquine and for the parasite count on admission to 
the study (h0) and at 24, 72, 168, 336, 504, and 672 hours 
after the administration of the drug. On day 1 (24 h), 
blood samples were collected immediately before the 
administration of the antimalarial drugs. Whole blood 
samples were centrifuged at 3,500 g for 10 min at 4 °C for 
plasma separation, and samples were immediately stored 
at -80 °C until analysis.
Measurement of chloroquine 
A reverse-phase HPLC system with fluorescence 
detection was used to measure the concentrations of 
chloroquine (Flexar, Perkin Elmer™, Shelton, MA US). 
The drug was extracted from plasma using a liquid-liquid 
procedure as described by Alvan et al.10 with modifications11. 
The column was an RP-18 (X terra 4.6 × 150 mm, 
i.d. 5-µm) at 25 °C, and the mobile phase was composed 
of dichloromethane-methanol-(1M) perchloric acid 
(100:9:1.2; v:v:v) at a flow rate of 1.2 mL/min. The eluate 
was checked by a fluorescence detector with a wavelength of 
E
xcitation 
= 340 nm and E
mission
= 380 nm. The limit of detection 
was 10 ng/mL, and the limit of quantification was 25 ng/mL. 
The linear assay range was 25 to 2000 ng/mL. The mean 
between and within-day coefficients of variation were 8.3% 
and 10.5%, respectively. The mean recovery was 95%. 
Desethyl-chloroquine, primaquine, carboxy-primaquine, 
mefloquine, carboxy-mefloquine, and acetaminophen did 
not interfere in the detection of chloroquine.
Parasite count
The parasite count was performed on Giemsa-stained 
thick blood films. An experienced microscopist examined 
the blood films using 100× (oil immersion) objectives12.
Samples size
A difference of 30% in the pharmacokinetic parameters 
of chloroquine between genders could modify the 
pharmacokinetic parameters of the drug. It was estimated 
that at least 16 patients completing the follow-up period 
would provide at least an 80% power of detection, with 
a 95% confidence interval and 30% difference in the 
pharmacokinetics parameters assessed between male and 
female patients12. 
Statistical analysis
Data are presented as means and ranges, frequencies of 
occurrence, or as medians and ranges. The pharmacokinetic 
parameters of chloroquine were estimated by a 
non-compartmental model. The dose of chloroquine was 
normalized for the patient’s weight. The following 
pharmacokinetic parameters were determined: the maximum 
concentration (C
max
) was derived directly from the whole 
blood concentration-time profile, the area under the curve 
(AUC
0−28
) from the time of chloroquine administration to the 
last measurable concentration was estimated by the linear 
trapezoidal rule, and the extrapolation to infinity (AUC
0−∞) 
was obtained by dividing the last measurable chloroquine 
concentration by λZ. The chloroquine concentrations were 
log-transformed and fitted a linear regression model to the 
terminal phase of the concentration-time profiles by using 
the method of least squares, which estimated the terminal 
elimination rate constant (λZ). The terminal elimination 
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half-life (t
1/2
) was obtained by dividing ln2 by λZ. The 
apparent oral clearance per fraction of drug absorbed (CL/f) 
was derived from the ratio of the dose to AUC
0−∞. The 
apparent volume of distribution (V/f) was obtained from 
CL/f divided by λZ. The concentrations of chloroquine 
were compared between the genders in each day of blood 
sampling by the Student t-test. The pharmacokinetic 
parameters of chloroquine were compared between the 
genders by the Student t-test. The data were analyzed in 
WinNonlin (version 3.3; Pharsight Corp, Mountain View, 
CA, USA). The significance level was set at 5%.
Ethical aspects
The research was approved by the Ethical Committee of 
the Nucleo de Medicina Tropical da Universidade Federal 
do Para (Brazil), Nº 2.819.240/2018. All patients admitted 
to the study signed the consent inform.
RESULTS
A total of 26 male and 25 female patients with malaria 
were admitted in the study. The baseline characteristics 
are shown in Table 1. All samples collected at admission 
to the study (h0) had no measurable chloroquine levels. In 
the clinical interviews, patients of both genders reported 
comparable frequencies of nausea (75%), pruritus (45%), 
insomnia (40%), dizziness (40%), and tinnitus (35%). 
There were no mensurable concentrations of chloroquine 
in plasma samples collected at admission in the study. 
Plasma concentrations of chloroquine at 24, 72, 168, 336, 
504 and 672 h in male and female patients were 402 ng/mL 
(145-891 ng/mL) and 451.8 ng/mL (110-745 ng/mL) 
(p=0.448), 1295 ng/mL (360-2450 ng/mL) and 1220 ng/mL 
Table 1 - Baseline characteristics of patients.
characteristics male (n=26) female (n=25)
Age (years) 26 (18-34) 25 (20-32)
weight (kga) 64 (54-82) 59 (55-78)
parasitemia on admissionb 1260 (3.52) 1145 (2.21)
parasite clearance time 
(hours)
60 (24-96) 60 (24-96)
previous episodes of malaria 
(%)
100 90
fever at admission, (%) 80 80
Hemoglobin (g/dLa) 13.2 (12-14) 12.6 (11-14)
haematocrit (%a) 39 (35-43) 34 (30-38)
platelets(mm3 X 1000a) 280 (210-340) 270 (190-320)
total dose of chloroquine 
administered (mg/kg)
23.9 (22-27) 24.6 (23-26)
aResults are expressed as means and ranges; bresults are 
expressed as geometrical means and standard deviations
(530-2245 ng/mL) (p=0.629), 527 ng/mL (345-774 ng/mL) 
and 496.7 ng/mL (295-794 ng/mL) (p=0.387), 201 ng/mL 
(147-284 ng/mL) and 192 ng/mL (137-236 ng/mL) 
(p=0.284), 121 ng/mL (48-159 ng/mL) and 124 ng/mL 
(940-145 ng/mL) (p=0.504), 70 ng/mL (31-104 ng/mL) 
and 65ng/mL (30-98 ng/mL) (p=0.421). The concentration-
time profile is shown in Figure 1. The pharmacokinetic 
parameters of chloroquine derived from the concentration-
time curve are shown in Table 2. Data were similar between 
male and female patients. All patients showed an adequate 
therapeutic response up to 28 days of follow-up.
DISCUSSION
In Brazil, there are no studies comparing the 
pharmacokinetic parameters of chloroquine betweengenders, 
which is relevant, as males and females are at risk for 
Anopheles bites13. Chloroquine is the antimalarial drug of 
choice to eliminate the asexual stages of P. vivax due to its 
safety and low cost8. The present study investigated whether 
the patient’s gender would change the pharmacokinetic 
parameters of the drug, which is relevant as the hormonal 
cycle of females, the use of oral contraceptives, pregnancy, 
body weight and fat distribution can influence the 
pharmacokinetic and the treatment outcomes of some 
drugs9. The pharmacokinetic parameters of chloroquine 
were estimated by a non-compartmental modeling, which 
provides a reliable assessment of pharmacokinetics 
parameters of the drug in sparse samples12,14. Despite whole 
blood samples tend to present with higher concentrations of 
chloroquine than plasma and serum samples, most studies 
assessing chloroquine exposure were performed in plasma 
or serum samples14-17. Furthermore, there was no significant 
pharmacokinetic interaction between chloroquine and 
primaquine, a partner drug, for the treatment of P. vivax 
malaria15.
Figure 1 – Concentration time-curve of chloroquine in female (■) 
and male patientes (●) with P. vivax malaria. Data are presented 
as mean values
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The baseline characteristics were comparable in male 
and female patients. There were no significant adverse 
reactions that could lead to the interruption of treatment, 
which confirms the safety and tolerability of the drug at 
a total dose of 25 mg/kg1,2. The total doses administered 
were similar in male and female patients, but the mean 
values were below the recommendations of the World 
Health Organization in both genders2. However, the low 
doses found in some patients did not modify the therapeutic 
response up to 28 days of follow-up, which suggests a 
downward revision of the total dose of 25 mg/kg proposed 
by WHO to treat the disease in different endemic scenarios.
Chloroquine tablets present oral bioavailability 
estimated at 89% in healthy volunteers. The main 
pharmacokinetic characteristics of the drug are the large 
volume of distribution and the long elimination half-life. 
Chloroquine is metabolized in the liver by CYP2C8 and, 
to a lesser extent, via CYP3A4 and CYP2D6 enzymes. The 
primary metabolite is desethyl-chloroquine, which retains 
the pharmacological activity of the parent drug5-8. The 
pharmacokinetic parameters of the study patients agreed 
with the long half-life and the large volume of distribution 
of the drug. Additionally, there was a high inter-individual 
variation in the estimated parameters, which is in line with 
previous reports on the pharmacokinetics of the drug5-8. 
The comparison of pharmacokinetic parameters of 
chloroquine between genders showed no significant 
differences, suggesting that there was no significant 
influence of the patient’s gender on the disposition of the 
drug. The mean C
max
 found in both genders was within the 
values of 996-2446 ng/mL reported in male Thai patients 
with P. vivax malaria under similar dosing regimen16. The t
1/2
 
agreed with values of 8.27-9.33 days found in Thai patients, 
as well as with values of 6-12.4 days reported in healthy 
Nigerians after a single dose of 600 mg16,17. The clearance in 
both genders was similar to the median values reported for 
Thai and Burmese patients with vivax malaria of 6.13 L/h18. 
The median value of the apparent volume of distribution 
was similar to the apparent volume of distribution in the 
peripheral compartment of 1600 L and within the range 
found for the sum of apparent volume of distribution of 
the central and peripheral compartments of 2068 L found 
in the above population groups18. 
The schedule of blood sampling of the study, with 
a small number of time points in the initial phase of 
distribution of the drug, could lead to an underestimation of 
the AUC
0−28
 and of the apparent volume of distribution. For 
instance, most of the values of AUC
0−28 
found in the study 
were within the values reported in Thai male patients, but 
the mean values found in both genders were lower than those 
found in the referred study, although higher than in healthy 
male Thai. There are several causes of disagreements in 
pharmacokinetic studies such as the dose regimen, blood 
sampling schedule, pharmacokinetic model used to estimate 
parameters, and parasite count on admission12,19. Thus, the 
differences between the data of the present study with those 
found in the Thai study could be related to the frequency of 
administration of chloroquine within 24 h of treatment16. 
CONCLUSION
In conclusion, the data of the present study revealed 
that chloroquine presents a similar pharmacokinetic 
disposition in bothgenders. . Thus, the same dose regimen 
of chloroquine provides a comparable pattern of exposure 
in male and female patients. 
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